CLINICAL TRIALS PROFILE FOR FIRVANQ KIT
✉ Email this page to a colleague
All Clinical Trials for FIRVANQ KIT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT06148025 ↗ | Antibiotics and Vaccine Immune Responses Study | Recruiting | Centenary Institute of Cancer Medicine and Cell Biology | Phase 4 | 2023-11-23 | The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system? |
NCT06148025 ↗ | Antibiotics and Vaccine Immune Responses Study | Recruiting | Flinders University | Phase 4 | 2023-11-23 | The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system? |
NCT06148025 ↗ | Antibiotics and Vaccine Immune Responses Study | Recruiting | Royal Adelaide Hospital | Phase 4 | 2023-11-23 | The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system? |
NCT06148025 ↗ | Antibiotics and Vaccine Immune Responses Study | Recruiting | Telethon Kids Institute | Phase 4 | 2023-11-23 | The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system? |
NCT06148025 ↗ | Antibiotics and Vaccine Immune Responses Study | Recruiting | University of Sydney | Phase 4 | 2023-11-23 | The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system? |
NCT06148025 ↗ | Antibiotics and Vaccine Immune Responses Study | Recruiting | South Australian Health and Medical Research Institute | Phase 4 | 2023-11-23 | The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system? |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FIRVANQ KIT
Condition Name
Clinical Trial Locations for FIRVANQ KIT
Clinical Trial Progress for FIRVANQ KIT
Clinical Trial Phase
Clinical Trial Sponsors for FIRVANQ KIT
Sponsor Name